Hoertkorn Richard Charles Esperion Therapeutics, Inc. Transaction History
Hoertkorn Richard Charles
- $177 Million
- Q2 2025
A detailed history of Hoertkorn Richard Charles transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Hoertkorn Richard Charles holds 2,000 shares of ESPR stock, worth $5,400. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,000
Previous 2,000
-0.0%
Holding current value
$5,400
Previous $2,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ESPR
# of Institutions
181Shares Held
106MCall Options Held
139KPut Options Held
604K-
Black Rock Inc. New York, NY14MShares$37.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$31.6 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.3MShares$27.9 Million0.05% of portfolio
-
Two Seas Capital LP Rye, NY9.95MShares$26.9 Million0.18% of portfolio
-
Pender Fund Capital Management Ltd. Vancouver, A16.68MShares$18 Million4.26% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $180M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...